NCT04317261View on ClinicalTrials.gov

Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria

NACompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2020

Conditions
HematuriaBladder Cancer
Interventions
DIAGNOSTIC_TEST

Xpert Bladder Cancer Monitor (Xpert Monitor) test and assay of urinary metabolomics (gene expression of CRAT and SLC)

Urine sample is evaluated for RNA and urinary metabolites

Trial Locations (1)

35516

Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT04317261 - Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With Hematuria | Biotech Hunter | Biotech Hunter